Muscarinic receptor Inhibitors
9 drugsAbout Muscarinic receptor
Muscarinic receptors are a family of GPCRs activated by acetylcholine, mediating smooth muscle contraction, glandular secretion, and heart rate regulation. Modulating these receptors offers therapeutic potential across various conditions due to their diverse physiological roles.
Genetic evidence weakly supports muscarinic receptors as therapeutic targets, with associations to insomnia (score 0.22) and corneal ulcer (score 0.19). Colocalization studies show strong eQTL/pQTL signals (max H4: 0.97), suggesting potential regulatory mechanisms.
Nine FDA-approved drugs target muscarinic receptors, including TRANSDERM SCOP, SOLIFENACIN SUCCINATE and VIZZ, all of which are small molecules. These drugs primarily address 'other' therapeutic areas (8 drugs) and respiratory conditions (1 drug).
Strategic Insights
ℹ️ How we calculate- White space opportunity in Urge Incontinence with only 2 trials.
Human Genetic Evidence
Genetic evidence offers weak support, with top associations to insomnia and corneal ulcer.
Further research is needed to validate the causal role of CHRM1 in disease.
Evidence Across Diseases
2 totalGWAS and other genetic studies link CHRM1 to 2 diseases.
🔗 Colocalization Evidence 2 strong
max H4: 0.97eQTL/pQTL signals for CHRM1 colocalize with these GWAS traits, providing causal evidence that gene expression changes drive disease risk.
Understanding these scores
Association Score (0-1): Combines all evidence types (genetic, literature, drugs, animal models). Higher = more evidence linking target to disease. This is a ranking heuristic, not a confidence score.
L2G Score: Open Targets uses a machine learning model (Locus-to-Gene) to predict which gene is causal at each GWAS locus. L2G=0.5 means ~50% probability of being the causal gene. Only associations with L2G > 0.05 are included.
Odds Ratio (OR): From gene burden studies (UK Biobank, AstraZeneca PheWAS). Measures how loss-of-function variants affect disease risk. OR<1 = protective (inhibiting target may help), OR>1 = risk (losing function causes disease).
Beta (β): Effect size for continuous traits. β<0 = protective, β>0 = risk.
Clinical Translation (~1.8x): Based on Nelson et al. 2015: drug targets with genetic evidence have ~2x higher success rates in clinical trials. We estimate: Strong support (score ≥0.7) → ~1.8x, Moderate (0.3-0.7) → ~1.3x, Weak → baseline.
Colocalization (H4): Tests whether a GWAS signal and an eQTL/pQTL signal share the same causal variant. H4 is the posterior probability that both traits are associated AND share a causal variant. H4 > 0.8 = strong evidence that gene expression/protein levels drive disease risk. This links genetic variation → gene expression → disease, supporting the target-disease connection.
Top Drugs
Nine companies have approved drugs, including GLENMARK PHARMS LTD and SCIEGEN PHARMS.
The presence of multiple players suggests a moderately competitive market.
| Drug | Company | Approved | Indications |
|---|---|---|---|
| SOLIFENACIN SUCCINATE | AJANTA PHARMA LTD | 2014 | 2 |
| TOVIAZ | Pfizer | 2008 | 2 |
| DETROL LA | UPJOHN | 2000 | 2 |
| VUITY | AbbVie | 2021 | 1 |
| VIZZ | LENZ THERAP | 2025 | 1 |
| QLOSI | ORASIS PHARMS | 2023 | 1 |
Drug Modality Landscape
Modalities
Routes of Administration
Muscarinic receptor is amenable to small molecule drugs, with oral options available for convenient dosing.
Exploring alternative modalities like antibodies or peptides could provide differentiation.
Clinical Trials 270 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 74 | 62 | 7 | 5 | 90% |
| Phase 2 | 49 | 34 | 7 | 8 | 83% |
| Phase 3 | 63 | 48 | 3 | 12 | 94% |
| Phase 4 | 84 | 67 | 9 | 8 | 88% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phase 3 Readout Calendar Pro
1 Phase 3 trial testing approved Muscarinic receptor drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting Muscarinic receptor. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
Drug Approval Timeline (1979 - 2025)
The first drug was approved in 1979 (TRANSDERM SCOP), with the most recent in 2025 (VIZZ).
The 47-year span suggests sustained interest, but recent approvals may indicate renewed focus.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 9 companies competing
- • Market share by company
Full Drug Portfolio
- • All 9 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 9-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 125 clinical trials targeting Muscarinic receptor.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities